Medication info
Seviduo Tablet 10/40 mg

Seviduo Tablet 10/40 mg

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›13.888mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
Round film-coated tablets of reddish-brown color
Packaging
Alu-Alu - 30 tablets/Alu-Alu [(10 tablets/Alu-Alu X 3)]
Approval status
Active

MFDS item code 201405005 · Approved 2014.10.29 · Insurance code 645404300

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. It is recommended, if possible, to take this medicine at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended for patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medicine must not be administered to patients with severe hepatic impairment. (See section 2, Patients who must not be administered this medicine, under Precautions for Use.) ∘Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.
Child dose
Safety and efficacy have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
View approved original text

This medication is used in the treatment of patients with essential hypertension whose blood pressure is not sufficiently controlled by monotherapy with amlodipine or olmesartan medoxomil. This therapy helps effectively lower blood pressure and reduce the risk of cardiovascular complications.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. It is recommended, if possible, to take this medicine at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended for patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medicine must not be administered to patients with severe hepatic impairment. (See section 2, Patients who must not be administered this medicine, under Precautions for Use.) ∘Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.

Child dose

Safety and efficacy have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn when taken during the second and third trimesters of pregnancy, so discontinuation should occur immediately if pregnancy is confirmed. People with hypersensitivity to any ingredient in this medication, pregnant or breastfeeding women, patients with severe liver impairment, severe heart valve disease, biliary obstruction, patients on dialysis, patients in shock, certain diabetes patients, and patients with severely impaired kidney function should not take it. Patients with fluid or salt depletion may experience hypotension, so careful observation of condition is necessary during the initial stages of treatment, and proper treatment is needed if blood pressure drops too low. Patients with severe heart valve stenosis or heart disease should be cautious as blood vessels may dilate and cause hypotension. In patients with impaired kidney function, kidney function may worsen, so it should be taken cautiously, and those with impaired liver function also need to be careful. During treatment with this medication, side effects such as dizziness, headache, hypotension, edema, dyspepsia, skin rash may occur. If any unusual symptoms arise, consultation with a healthcare professional is urged. It is important to inform your doctor or pharmacist if taking other medications for hypertension, as drug interactions may occur. It is generally recommended to avoid the use of this medication during pregnancy, and consultation with a physician is necessary if planning pregnancy or during pregnancy. If breastfeeding, it is recommended to either stop breastfeeding or discontinue the medication because this medicine can be passed into breast milk and affect the infant. Children under 18 years old should not take this medication as its safety and efficacy have not been established. Elderly patients should start with a lower dose and observe their condition carefully as liver, kidney, or heart function may be impaired. In case of overdose, blood pressure may drop excessively and heart rate may increase, so you must visit a medical institution immediately for proper treatment. Store this medication out of reach of children, avoiding direct sunlight and humidity.

Side effects

Drug hypersensitivity, hyperkalemia, decreased libido, dizziness, headache, orthostatic hypotension, drowsiness, paresthesia, sensory decrease, syncope, vertigo, palpitations, tachycardia, hypotension, orthostatic hypotension, dyspnea, cough, nausea, vomiting, dyspepsia, diarrhea, constipation, dry mouth, abdominal pain, rash, urticaria, muscle tension, limb pain, low back pain, frequent urination, erectile dysfunction, peripheral edema, edema, pitting edema, fatigue, asthenia, facial edema, decreased serum potassium, increased serum creatinine, increased serum uric acid, increased gamma-glutamyl transferase, decrease in hemoglobin and hematocrit, cholelithiasis, female breast neoplasm, exacerbation of cerebral infarction, gum bleeding, orthostatic dizziness, chest pain, cold, increased CRP, fever, hemoptysis, excessive sneezing, runny nose, laryngitis, arthritis, flank pain, generalized pain, hypoglycemia, weight loss, heartburn, gastroenteritis, herpes zoster, diplopia, asthenia, angioedema, chronic malabsorption syndrome-like intestinal disease, intestinal vascular edema, rhabdomyolysis, acute kidney failure, hair loss, itching, urticaria, autoimmune hepatitis, angioedema, angioedema, leukopenia, thrombocytopenia, toxic epidermal necrolysis, flushing, fatigue, edema, palpitations, dizziness, headache, drowsiness, abdominal pain, nausea, jaundice, elevated liver enzymes, non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a sealed container. It is best to maintain room temperature between 1 and 30 degrees Celsius to preserve the medication's effectiveness.

Appearance and packaging

Appearance

Round film-coated tablets of reddish-brown color

Package unit

Alu-Alu - 30 tablets/Alu-Alu [(10 tablets/Alu-Alu X 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.